Key Highlights
- Johnson & Johnson secured FDA clearance for Icotyde, an oral plaque psoriasis medication created alongside Protagonist Therapeutics (PTGX), triggering a ~4.69% decline in ABBV shares
- The new once-daily pill represents a significant competitive threat to AbbVie’s leading immunology franchise drug Skyrizi
- Wall Street forecasters remain optimistic about Skyrizi’s prospects, anticipating 23% revenue expansion through fiscal year 2026
- Technical indicators show ABBV trading beneath its 20-day ($227.73), 50-day ($224.27), and 200-day ($214.95) simple moving averages, signaling bearish sentiment
- Management issued fiscal 2026 earnings per share projections of $14.37–$14.57 while unveiling a strategic collaboration with Alloy Therapeutics for antibody research
Shares of AbbVie (ABBV) tumbled approximately 4.69% during Tuesday’s trading session following the Food and Drug Administration’s authorization of Johnson & Johnson’s (JNJ) innovative plaque psoriasis medication, Icotyde. The regulatory approval sparked concern among market participants due to Skyrizi’s critical importance to AbbVie’s expansion strategy beyond Humira.
Developed through a partnership between J&J and Protagonist Therapeutics (PTGX), Icotyde offers patients a convenient once-daily oral formulation for managing plaque psoriasis. This positions the medication as a head-to-head challenger to Skyrizi, which stands as AbbVie’s flagship immunology asset and a cornerstone of its revenue generation.
Despite the intensifying competitive landscape, Wall Street researchers maintain confidence in Skyrizi’s market position. The drug’s strong clinical performance and administration schedule are viewed as differentiating factors, with forecasts indicating 23% revenue growth reaching into fiscal 2026.
The equity finished trading near $212.50 following an opening below the previous day’s settlement price of $218.60. Intraday price action spanned from a low of $209.42 to a high of $218.60, demonstrating considerable downward pressure throughout the session.
Chart Analysis Signals Weakness
From a technical perspective, ABBV currently trades beneath its 20-day simple moving average ($227.73), 50-day SMA ($224.27), and marginally below its 200-day SMA ($214.95). This configuration across all primary moving averages indicates sustained selling momentum.
Both intraday and weekly Relative Strength Index measurements reflect selling conditions. Commodity Channel Index and Bollinger Band Position metrics suggest oversold territory with negative price momentum. The Average Directional Index remains subdued, indicating the absence of a defined directional trend, while the Moving Average Convergence Divergence indicator holds at neutral.
Immediate support emerges at $210.83, with a violation of this threshold potentially triggering additional downward movement. Overhead resistance appears at the Ichimoku Kijun indicator line positioned at $227.58.
Market participants are monitoring a potential range-bound scenario between $210.83 and $215.22, with select traders anticipating a possible bounce should price action consolidate near the lower boundary.
The 200-day moving average at $214.95 could provide temporary support going forward, though the preponderance of technical evidence maintains a bearish tilt.
Legacy Product Challenges and Aesthetics Weakness
The competitive pressure from Icotyde emerges during a challenging period for AbbVie. The pharmaceutical giant continues navigating the aftermath of patent expiration for blockbuster Humira, while its aesthetic medicine division — featuring products like Juvederm — experiences persistent revenue declines.
Several institutional investors have reduced their ABBV holdings in recent periods, signaling evolving market sentiment surrounding the company’s prospects. Corporate insider transactions have also tilted bearish, with two separate selling events recorded over the previous three months and zero purchasing activity.
On a more constructive note, AbbVie unveiled a long-term strategic alliance with Alloy Therapeutics focused on building a sophisticated antibody discovery infrastructure. The agreement features initial payments along with milestone-linked financial commitments, demonstrating ongoing dedication to research and development initiatives.
AbbVie’s leadership team also provided fiscal 2026 earnings guidance ranging from $14.37 to $14.57 per share, which certain observers interpret as evidence of management’s confidence in the organization’s fundamental business trajectory.
The Street consensus price objective stands at $251.44, accompanied by a recommendation rating of 2.2 — indicating a moderate buy stance. Institutional ownership concentration remains elevated at 74.71%.
ABBV’s GF Value calculation indicates a fair value estimate of $198.80, suggesting the shares are currently trading at reasonable valuation levels based on this methodology.
